132 related articles for article (PubMed ID: 20219069)
1. CD133 expression in rectal cancer after preoperative chemoradiotherapy.
Kojima M; Ishii G; Atsumi N; Nishizawa Y; Saito N; Ochiai A
Cancer Sci; 2010 Apr; 101(4):906-12. PubMed ID: 20219069
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients.
Shinto E; Hashiguchi Y; Ueno H; Kobayashi H; Ishiguro M; Mochizuki H; Yamamoto J; Hase K
Dis Colon Rectum; 2011 Sep; 54(9):1098-106. PubMed ID: 21825889
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
6. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
8. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
[TBL] [Abstract][Full Text] [Related]
9. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
12. [Association of CD133 expression and sensitivity of rectal cancer to preoperative radiotherapy].
Qiu JM; Yang GG; Lu XJ; Wang X; Shen Z; Zhang XF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Oct; 15(10):1066-9. PubMed ID: 23099908
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
Mizukami T; Kamachi H; Mitsuhashi T; Tsuruga Y; Hatanaka Y; Kamiyama T; Matsuno Y; Taketomi A
BMC Cancer; 2014 Sep; 14():687. PubMed ID: 25240521
[TBL] [Abstract][Full Text] [Related]
17. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
[TBL] [Abstract][Full Text] [Related]
18. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.
Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W
Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781
[TBL] [Abstract][Full Text] [Related]
19. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.
Choi D; Lee HW; Hur KY; Kim JJ; Park GS; Jang SH; Song YS; Jang KS; Paik SS
World J Gastroenterol; 2009 May; 15(18):2258-64. PubMed ID: 19437567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]